5 days ago
During World Thyroid Awareness Week: Merck Launches a New Dosage of Euthyrox 75 Micrograms - Sponsored
As part of its ongoing efforts to raise awareness about thyroid-related diseases, Merck Limited Egypt announced the launch of a new dosage of 'Euthyrox 75 micrograms' in the Egyptian market.
This announcement was made during the events of the International Thyroid Awareness Week on May 30, 2025, with the participation of 350 healthcare professionals from across Egypt, in addition to 14 expert speakers and session chairs in the field of endocrinology.
Hypothyroidism is one of the most common diseases affecting millions worldwide. Patients suffer from reduced thyroid gland activity, which leads to a drop in thyroid hormone levels in the body. Thyroid disorders are among the most widespread endocrine disorders globally, ranking second only to diabetes, with up to 10% of the population affected—making it a major public health concern. It is also one of the leading causes of fatigue, weight gain, depression, heart problems, and other symptoms.
Through this event, Merck aimed to raise awareness about the importance of early diagnosis and effective treatment of thyroid disorders. Treatment using synthetic thyroid hormones such as 'Euthyrox' can help restore hormonal balance.
Merck is considered a leading company in the field of healthcare and is committed to its social and medical responsibility toward patients with hypothyroidism. With the launch of the new 75 microgram dosage of 'Euthyrox,' the company reaffirms its ongoing support for patients.
Dr. Ibrahim Naguib Al-Ebeirashy, Professor of Internal Medicine and Endocrinology at Qasr Al-Ainy and former Head of Internal Medicine Departments at Qasr Al-Ainy, stated that the availability of the 75 microgram dosage of Euthyrox will benefit patients who require precise dose adjustments to avoid hormonal fluctuations.
Dr. Sherif El-Seddawy, General Manager and Executive Director of Merck, confirmed that the launch of the new 'Euthyrox 75 micrograms' dosage reflects continued support for patients, alongside the company's commitment to raising awareness about hypothyroidism. He emphasized Merck's ongoing efforts to accelerate scientific and medical initiatives for the benefit of patients.
Furthermore, Merck Limited Egypt praised and appreciated the Egyptian Drug Authority as a strategic partner for its ongoing collaboration and efforts to increase awareness among patients and physicians.
Dr. Cyrine Hammami, Regional Head of Cardiometabolic and Endocrine Diseases for the Middle East, Africa, and Russia, expressed the company's pride in launching Euthyrox 75 micrograms in the Egyptian market, emphasizing that raising awareness about hypothyroidism is an important step for the community.
In this context, Dr. Mohamed Ismail, Head of the Cardiometabolic and Endocrine Business Unit at Merck Limited Egypt, stated that offering multiple dosage options, such as 75 micrograms, helps patients avoid the complications of manual dose adjustment.
Dr. Rania Rafiq, Medical Affairs Director, highlighted that raising awareness about hypothyroidism remains one of the company's top priorities, especially since the symptoms can be vague and often diagnosed only after long periods of suffering. Therefore, shedding light on this occasion is of great importance.
Follow us on:
Facebook
Instagram
Whatsapp
Short link:
